The Effects of Vasopressin on Attention Control

Sponsor

University of Electronic Science and Technology of China (Other)

Overall Status

Completed

CT.gov ID

NCT04493554

Collaborator

(none)

Enrollment

Location

Arms

5.2

Actual Duration (Months)

17.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) could influence attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: Vasopressin Drug: Placebo	N/A

Detailed Description

A number of previous studies have reported vasopressin's effect on human social behavior and social cognition, although it remains unclear whether vasopressin could modulate attention allocation including stimulus-driven bottom-up control and goal-directed top-down control. In the current randomized, between-subject, placebo controlled study, 89 healthy male subjects will be recruited and receive either vasopressin (20 IU) or placebo control administered intranasally. 45 minutes after treatment subjects will be required to complete a social-emotional saccade /antisaccade eye-tracking paradigm. The paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of vasopressin.

Study Design

Study Type:

Interventional

Actual Enrollment :

89 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking designBetween-subject randomized placebo-controlled double-blind pharmacological eye-tracking design

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Basic Science

Official Title:

The Effects of Vasopressin on Attention Control: An Eye-tracking Study

Actual Study Start Date :

Jul 28, 2020

Actual Primary Completion Date :

Nov 30, 2020

Actual Study Completion Date :

Jan 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Vasopressin Vasopressin (20 IU) intranasally	Drug: Vasopressin Administration of vasopressin (20 IU) intranasally
Placebo Comparator: Placebo Placebo intranasally	Drug: Placebo Administration of placebo intranasally

Arm

Intervention/Treatment

Experimental: Vasopressin

Vasopressin (20 IU) intranasally

Drug: Vasopressin

Administration of vasopressin (20 IU) intranasally

Placebo Comparator: Placebo

Placebo intranasally

Drug: Placebo

Administration of placebo intranasally

Outcome Measures

Primary Outcome Measures

Effect of vasopressin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli [45 minutes - 100 minutes after treatment]
Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions
Effect of vasopressin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli [45 minutes - 100 minutes after treatment]
Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions

Secondary Outcome Measures

Emotion-specific effects of vasopressin administration on saccade/antisaccade latencies towards the separate facial emotions [45 minutes - 100 minutes after treatment]
Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions
Emotion-specific effects of vasopressin administration on saccade/antisaccade error rates for the separate facial emotions [45 minutes - 100 minutes after treatment]
Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin and placebo treatment conditions

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 30 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Healthy participants
Non smokers

Exclusion Criteria:

Previous or current medical, psychiatric, neurological disorder
Regular medication
Use of any psychoactive substances in the 24 hours before experiment
Contra-indications for vasopressin
Contra-indications for eye-tracking data acquisition

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Electronic Science and Technology of China(UESTC)	Chengdu	Sichuan	China	611731

Sponsors and Collaborators

University of Electronic Science and Technology of China

Investigators

Principal Investigator: Keith Kendrick, PhD, University of Electronic Science and Technology of China (UESTC)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Keith Kendrick, Professor, University of Electronic Science and Technology of China

ClinicalTrials.gov Identifier:

NCT04493554

Other Study ID Numbers:

UESTC-neuSCAN-70

First Posted:

Jul 30, 2020

Last Update Posted:

Jan 7, 2021

Last Verified:

Jan 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Vasopressins

Arginine Vasopressin

Study Results

No Results Posted as of Jan 7, 2021